Fidthera

Fidthera is a biotechnology company focused on developing next-generation cell therapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary platform to engineer T cells with enhanced specificity and durability, aiming to overcome the limitations of current adoptive cell transfer approaches. By focusing on novel T cell receptor (TCR) discovery and optimization, Fidthera seeks to provide more effective and safer therapeutic options for patients with high unmet medical needs. The company's pipeline is currently in the pre-clinical stage, with multiple programs targeting various solid tumors and inflammatory conditions.